Top Markets
Coin of the day
Genenta Science S.p.A. Genenta Science S.p.A.

Genenta Science S.p.A.

GNTA
Rank in Stocks #28058
Genenta Science S.p.A. is an Italian clinical-stage biotechnology firm focused... Genenta Science S.p.A. is an Italian clinical-stage biotechnology firm focused on pioneering hematopoietic stem cell gene therapies to combat solid tumors. Its primary therapeutic candidate, Temferon, is currently undergoing Phase 1/2a clinical evaluation. This innovative therapy is being developed to treat glioblastoma multiforme, specifically targeting patients whose tumors exhibit an unmethylated MGMT gene promoter. Beyond this, Genenta Science is exploring Temferon's potential application in various other solid tumor types, including locally advanced hepatocellular carcinoma and intra-hepatic cholangiocarcinoma. Established in 2014, the company maintains its headquarters in Milan, Italy.
Share Price
$1.51
Last synced: 2026-07-31
Market Cap
$28.82M
Change (1 day)
-0.33%
Change (1 year)
-57.49%
Country
IT
Trade Genenta Science S.p.A. (GNTA)

Category

Earnings for Genenta Science S.p.A. (GNTA)
Earnings in 2026 TTM: 0
According to Genenta Science S.p.A. latest financial reports the company's current earnings are 0. In 2026 the company made an earning of 0, equal to its 2026 earnings that were of 0. The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.
Earnings history for Genenta Science S.p.A. from 2026 to 2026
Earnings at the end of each year
Year Earnings Change
Not enough data for the provided dates.
Earnings for similar companies or competitors
Company Earnings Earnings Difference Country
$5.27B -
US
$-3.09B -
US
$1.95B -
NL
$1.61B -
AU
- -
CH